articles
- Immunogenic Chemotherapy Enhances Recruitment of CAR-TCells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade. 39:193-208. 2021
- Intratumor heterogeneity: The Rosetta Stone of therapy resistance. 37:471-484. 2020
- Therapeutic targeting of CDK12/CDK13 in triple-negative breast cancer. 36:545-558. 2019
- Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis. 35:916-931. 2019
- Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting. 35:489-503. 2019
- NRF2 and the hallmarks of cancer. 34:21-43. 2018
- EWS/FLI confers tumor cell synthetic lethality to CDK12 inhibition in Ewing sarcoma. 33:202-216. 2018
- Employing metabolism to improve the diagnosis and treatment of pancreatic cancer. 31:5-19. 2017
- MUC1 and HIF-1alpha signaling crosstalk induces anabolic glucose metabolism to impart gemcitabine resistance to pancreatic cancer. 32:71-87. 2017
- An LXR-cholesterol axis creates a metabolic co-dependency for brain cancers. 30:683-693. 2016
- EZH2 and BCL6 cooperate to assemble CBX8-BCOR complex to repress bivalent promoters, mediate germinal center formation and lymphomagenesis. 30:197-213. 2016
- A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy. 29:117-129. 2016
- Targeting aberrant epigenetic networks mediated by PRMT1 and KDM4C in acute myeloid leukemia. 29:32. 2016
- Efficacy of retinoids in IKZF1-mutated BCR-ABL1 acute lymphoblastic leukemia. 28:343-356. 2015
- Broad anti-tumor activity of a small molecule that selectively targets the Warburg effect and lipogenesis. 28:42-56. 2015
- Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome. 27:644-657. 2015
- Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. 27:327-341. 2015
- MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer. 25:469-483. 2014
- Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma. 25:516-529. 2014
- The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity. 23:332-346. 2013
- Platelets alter tumor cell attributes to propel metastasis: programming in transit. 20:553-554. 2011
- An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. 20:384-399. 2011
- A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions. 19:527-540. 2011
- A stapled p53 helix overcomes HDMX-mediated suppression of p53. 18:411-422. 2010
- Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. 18:258-267. 2010
- Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. 14:299-311. 2008
- The inhibition of tumor cell intravasation and subsequent metastasis via regulation of in vivo tumor cell motility by the tetraspanin cd151. 13:221-234. 2008
- The DARC side of metastasis: shining a light on KAI1-mediated metastasis suppression in the vascular tunnel. 10:177-178. 2006
- Targeting ornithine decarboxylase in myc-induced lymphomagenesis prevents tumor formation. 7:433-444. 2005
- Inhibition of NF-kappa B in cancer cells converts inflammation-induced tumor growth mediated by TNF alpha to TRAIL-mediated tumor regression. 6:297-305. 2004
- Targeted disruption of beta 1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. 6:159-170. 2004
- Naturally death-resistant precursor cells revealed as the origin of retinoblastoma. 5:513-515. 2004
- Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. 4:321-328. 2003